Amid the AI gold rush, a new company forms to vet models and root out weaknesses
The market for artificial intelligence in health care is about as transparent as a brick wall. New tools achieve impressive results in published studies. But it is often difficult to compare them head to head with similar products, or tell whether they will work on different kinds of patients.
A new company is promising to change that — if it can convince AI developers to expose their products to more rigorous testing.
